In this role, Romanelli will have P&L responsibility for Merck’s US $22 billion international human health business and lead a team of 14,000 colleagues in more than 75 markets outside of the U.S
Supply increase to help meet growing global demand
No new studies have been requested
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Company expects strong organic growth in sales, EBITDA in 2022
Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
In the interim, Deepak Khanna will lead Human Health International.
Subscribe To Our Newsletter & Stay Updated
